subscribeSubscribe
Akeso Presented Promising Results of Cadonilimab and Lenvatinib

Akeso Presented Promising Results of Cadonilimab and Lenvatinib
PR NEWSWIRE
23 Jan 2024
Share Share
Fostrox + Lenvima shows improved rates to progression in advanced liver cancer

Fostrox + Lenvima shows improved rates to progression in advanced liver cancer
PR NEWSWIRE
17 Jan 2024
Share Share
Merck-Eisai`s endometrial cancer therapy combo fails first-line treatment trial

Merck-Eisai`s endometrial cancer therapy combo fails first-line treatment trial
REUTERS
09 Dec 2023
Share Share
Merck and Eisai`s cancer combo flops 2 more trials

Merck and Eisai`s cancer combo flops 2 more trials
Fraiser Kansteiner FIERCE PHARMA
23 Sep 2023
Share Share
Medivir reports promising interim data

Medivir reports promising interim data
PR NEWSWIRE
04 Sep 2023
Share Share
Merck and Eisai to stop Keytruda plus Lenvima trial in head and neck cancer

Merck and Eisai to stop Keytruda plus Lenvima trial in head and neck cancer
Lei Lei Wu ENDPTS
26 Aug 2023
Share Share
Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included
PR NEWSWIRE
14 Aug 2023
Share Share
OS Data Confirm Pembrolizumab/Lenvatinib as a Frontline Option in Advanced RCC

OS Data Confirm Pembrolizumab/Lenvatinib as a Frontline Option in Advanced RCC
ONCLIVE
08 Jul 2023
Share Share
Shilpa Medicare launches Lenvatinib Capsules in India under the brand Lenshil

Shilpa Medicare launches Lenvatinib Capsules in India under the brand Lenshil
INDIAN PHARMA POST
30 Jun 2023
Share Share
Merck, Eisai to discontinue late-stage study for skin cancer

Merck, Eisai to discontinue late-stage study for skin cancer
BUSINESSWIRE
08 Apr 2023
Share Share